Loading
Loading
Organ & Bioregulator Research · 20mg
Janoshik-tested · 10 vials per kit
Livagen is a synthetic tetrapeptide bioregulator studied in preclinical research for its hepatoprotective and immune-modulating properties. Research has examined its potential to modulate digestive enzyme activity, inhibit enkephalin-degrading enzymes, improve antioxidant status, promote liver function recovery in hepatitis models, and activate chromatin in lymphocytes. Studies have also explored its role in delaying cellular aging.
≥98%
Purity
Lyophilised
Format
2–3 wks
Arrival
Don't want to wait 3 weeks?
Check local stock — weekday same/next-day delivery available.
Chemical Properties
Need to work out your dose?
Use our reconstitution calculator — syringe units in seconds.
Research Use Only — Disclaimer
This product is intended solely as a research chemical for laboratory and scientific study purposes only. It is not approved by the TGA or any regulatory body for human or animal consumption, therapeutic use, or clinical application. The information provided on this website is for educational purposes only. Handling must be limited to suitably qualified professionals operating within applicable laws and regulations. This product is not classified as a drug, food, cosmetic, or medicinal product and must not be used or labelled as such. By purchasing, you confirm you are a qualified research professional and accept full responsibility for compliance with all relevant laws in your jurisdiction.
Livagen
Livagen is a synthetic tetrapeptide (Lys-Glu-Asp-Ala) developed as a liver and immune system bioregulator in the Khavinson series. It is studied for hepatoprotective and immunomodulatory properties in the context of age-related decline and toxic hepatic stress models.
Livagen has been shown to interact with chromatin in hepatocytes, potentially upregulating genes related to hepatocellular repair and antioxidant enzyme production. Immunological effects include stimulation of lymphocyte activity, suggesting both hepatic and systemic immune targets.
Animal studies document hepatoprotective effects in ethanol and hepatotoxin-induced liver damage models, with improved liver enzyme profiles and reduced histological damage. Immune-stimulating effects have been studied in post-radiation and chemotherapy-induced immunodeficiency models.
For research reference only. All information pertains to preclinical or published human trial data. Not intended as medical advice. This product is for research use only.
Don't have supplies? Grab them while you're here.
